

May 19, 2025

Consolidated Financial Results for the Year Ended March 31, 2025 (FY2024)

Presentation for Investors



Securities code : 4886 (TSE)

ASKA Pharmaceutical Holdings Co., Ltd.

Financial Results Summary for FY2024



Atsushi Maruo,
Senior Managing Member of the Board of Directors, Representative Director
ASKA Pharmaceutical Holdings Co., Ltd.

FY2024 Financial Results and Highlights

Net sales

✓ **64.1 billion yen, increased 2.1% YOY**

Record-high sales based on the growth of our pharma business and animal health business

Cost of sales

✓ **32.8 billion yen, COS ratio improved 0.1 percentage points YOY**

Maintained the same level COS ratio by implementing Product Mix strategy to deal with rising raw material cost and other costs

SG&A expenses

✓ **26.0 billion yen, SGA ratio increased 2.0 percentage points YOY**

Increased due to costs associated with research and development progress despite decreased depreciation

Operating profit

✓ **5.3 billion yen, decreased 18.0% YOY**

Decreased due to the increased R&D expenses that exceeded the increase in Gross Profit

Consolidated Statements of Income/Net Sales by Business Segment

(Millions of yen)	FY2023 Apr - Mar Actual	FY2024 Apr - Mar Actual	Actual +/-	Growth +/-
Net sales	62,843	64,139	1,296	2.1%
Cost of sales	32,178	32,803	625	2.0%
Gross profit	30,664	31,335	670	2.2%
Selling, general and administrative expenses	24,164	26,003	1,839	7.6%
Operating profit	6,500	5,331	(1,168)	(18.0)%
Ordinary profit	6,522	5,107	(1,414)	(21.7)%
Profit attributable to owners of parent	7,545	5,101	(2,444)	(32.4)%

Consolidated Net Sales by Business Segment

(Millions of yen)	FY2023 Apr - Mar Actual	FY2024 Apr - Mar Actual	Breakdown	Actual +/-	Growth +/-
Pharmaceutical business	56,016	56,655	88.3%	639	1.1%
Animal health business	6,664	7,246	11.3%	581	8.7%
Other businesses	162	237	0.4%	74	45.8%
Total	62,843	64,139	100.0%	1,296	2.1%

Sales of Main Products (Pharmaceutical Business)

(Millions of yen)

Area	Category	Products (generic name)	FY2023 Apr - Mar	FY2024 Apr - Mar		FY2025 Apr - Mar		Notes (FY2024)
			Actual	Actual	YOY	Forecast	YOY	
Internal Medicine	AG	CANDESARTAN ¹ (candesartan)	9,593	8,545	(10.9)%	7,112	(16.8)%	- Affected by the NHI drug price reduction - Sales volume remained almost same
	Brand-name	THYRADIN (levothyroxine)	7,862	8,113	3.2%	8,628	6.3%	Solid sales growth due to increased disease awareness, etc.
	Brand-name	RIFXIMA (rifaximin)	5,864	6,455	10.1%	7,458	15.5%	Good sales growth as the Guideline became accepted
	Brand-name	MERCAZOLE (thiamazole)	1,521	1,567	3.0%	1,629	4.0%	Progress as expected
	Generic	AMLODIPINE (amlodipine)	840	797	(5.1)%	756	(5.2)%	Affected by the NHI drug price reduction
Obstetrics and Gynecology	Brand-name	RELUMINA (relugolix)	9,906	10,531	6.3%	11,241	6.7%	Focused on expanding our market share in the endometriosis market
	Generic	DroEthi (drospirenone/ethinylestradiol)	6,125	7,502	22.5%	6,064	(19.2)%	Significant progress beyond expectations
	AG	FREWELL (norethisterone/ethinylestradiol)	3,303	3,149	(4.6)%	2,824	(10.3)%	- Affected largely by the NHI drug price reduction - Sales volume increased
	Brand-name	LUTEUM (progesterone)	2,029	2,349	15.8%	2,228	(5.1)%	Sales remain solid
	Brand-name	ANGE (levonorgestrel/ethinylestradiol)	725	676	(6.8)%	669	(1.0)%	Continued to make prescription proposals to doctors
	Brand-name	MAGSENT ² (magnesium sulfate)	706	723	2.3%	580	(19.8)%	Progress as expected
Urology	Generic	LEUPRORELIN ³ (leuporelin)	4,430	4,003	(9.6)%	3,814	(4.7)%	Affected by the NHI drug price reduction

1. Including fixed dose combination

2. Total value of magnesium sulfate preparation

3. 1.88mg formulation is only for gynecological indications but combined with 3.75mg formulation



Sales by Major Business Field (Animal Health Business)

(Millions of yen)


Business field	FY2023 (Apr – Mar)	FY2024 (Apr – Mar)		FY2025 (Apr – Mar)	
	Actual	Actual	YOY	Forecast	YOY
Feed additives Mixed feed Feed materials	4,042	4,584	13.4%	4,257	(7.1)%
Veterinary pharmaceuticals	2,487	2,601	4.6%	2,869	10.3%

Major Factors

- ❑ FY2024: Sales increased due to the growth of feed additives and veterinary pharmaceuticals.
- ❑ FY2025: Sales of feed additives are forecasted to decline because of the market conditions; however, sales of veterinary pharmaceuticals are expected to increase.

Analysis of FY2024 Operating Profit (vs FY2023)


(Millions of yen)



Major Factors

- ❑ Increased gross profit due to increased revenue and improved cost of sales ratio.
- ❑ Decrease in depreciation due to decreased amortization expenses for distributorship, etc.
- ❑ Increased costs for sales promotion, travel expenses, etc., due to revitalization of business activities.
Increased R&D costs due to uptick in drug discovery research, and progress in clinical trials.

Consolidated Balance Sheet



Major Factors

- ❑ The acquisition of Hataphar as a consolidated subsidiary caused our assets, liabilities, and net assets to increase.
- ❑ The inclusion of Hataphar's balance sheet (equity ratio 52.1%) caused our equity ratio to decrease by 3.2% to 65.0%.
- ❑ The goodwill recorded (4,361 million yen) is scheduled to be amortized over a period of 15 to 20 years.


Consolidated FY2025 Performance Forecast

(Millions of yen)	FY2024 Actual	FY2025 Forecast	YOY Actual +/-	YOY Growth +/-
Net sales	64,139	75,000	10,860	16.9%
Operating profit	5,331	6,800	1,468	27.5%
Ordinary profit	5,107	6,800	1,692	33.1%
Profit attributable to owners of parent	5,101	5,200	98	1.9%

Major Factors

- ❑ Net sales: Expected to increase due to growth in sales of mainstay products such as RIFXIMA, THYRADIN, and RELUMINA in the pharmaceutical business, as well as the consolidation of Hataphar.
- ❑ Profit: Operating profit, ordinary profit, and profit attributable to owners of parent are all projected to increase due to increase in gross profit and decrease in R&D expenses, etc.

Forecast of FY2025 Operating Profit (vs FY2024)




Major Factors

- ❑ Increased depreciation (including goodwill amortization), promotion expense, travel cost (due to expansion of operation)
- ❑ Increased gross profit and decreased R&D expenses by completing large-scale clinical studies
- ❑ Expects increased profit in the end by counting consolidation of Hataphar in

Capital Expenditures, Depreciation, and R&D Expenses¹


Capital Expenditures

(Tangible and software transfer basis)
(Millions of yen)




Depreciation

(Tangible/intangible total)
(Millions of yen)



R&D Expenses


(Millions of yen)



Major Factors

Capital Expenditures:	Expected to remain at the same level as the previous fiscal year due to continued capital expenditures for renovations to the formulation building at Iwaki Factory.
Depreciation:	Expected to exceed the previous fiscal year due to the start of operations at the renovated formulation building at Iwaki Factory.
R&D Expenses:	Expected to fall below the previous fiscal year due to completion of large-scale clinical studies, despite continued active discovery research and progress in clinical trials.

1. Overseas subsidiaries are not counted in the calculations. Also, depreciation does not include goodwill amortization.




About Action to Implement Management That Is Conscious of Cost of Capital and Share Price

Efforts to swiftly achieve a PBR (price-to-book ratio) of above 1x, and trends in PBR and ROE

- 1 Growth strategy
- 2 Strengthen shareholder return
- 3 Strengthen IR activities

In addition to the above, we are proactively striving to promote ESG management, as well as management based on capital costs and stock prices



Our PBRs are improving after the disclosure on “ASKA Pharmaceutical Holdings Takes Action to Implement Management That is Conscious of Cost of Capital and Share Price” in November 2023.

* Our PBRs are calculated based on the stock prices as of the end of each fiscal years. The statistics for FY2019 and FY2020 are for ASKA Pharmaceutical Co., Ltd. The statistics thereafter are for ASKA Pharmaceutical Holdings Co., Ltd.

Detail of Initiatives 1) Growth Strategy (Optimization of Cash Allocation)

FY2023-2025 Plan (disclosed in November 2023)

FY2023-2024 Results

(in JPY)


Source of funds	Investment		Objectives	Distribution
Operating CF※ 20.0 billion	For Growth	Pharma business	Expand pipelines by strengthening R&D and BD	15 billion +X
		New business	Femtech, CVC, Digital Health	
			Clinical lab tests & Animal health (Companion animals)	
		Overseas	Establish business in SE Asia	
		M&A	Acquire competencies for growth	
Cash from sale of cross-shareholdings 3.0 billion	Strengthen management base		Renew & expand production facilities	3-4 billion
			Digital transformation	
			Investment in human capital	
Fundraising (+X)	Shareholder return		Dividends, share buybacks	3-4 billion

Funds obtained	Major investments	
Operating CF※ 19.7 billion	About 12.9 billion	R&D Expenses (except tangible expenses) LF111, AKP-022, etc.
		Overseas business Consolidation of Hataphar as a subsidiary
		Investment in CVC, etc.
Cash from sale of cross-shareholdings 4.4 billion	About 4.2 billion	Clinical lab tests, Animal health
		Facility investment (tangible)
	Human capital investment	
	About 2.6 billion	Increased annual dividends per share to 55 yen

※ Assumed Operating Profit + Depreciation + R&D Expenses (excepting tangible expenses)

Detail of Initiatives 2) Strengthen Shareholder Returns

Changes in dividends per share



Shareholder return policy

Starting from FY2024, the Company sets forth **a benchmark for a consolidated dividend payout ratio of 30%** as a performance-linked profit distribution. Our basic policy calls for ongoing stable dividends while ensuring profit distribution linked to business performance, with a **minimum annual dividend of 30 yen per share**.

[FY2024 Planned]

Annual dividends of 55 yen, increased 15 yen compared to FY2023, per share is planned to be resolved at the AGM.

[FY2025 Forecast]

Annual dividends: 55 yen per share

Steadily implementing the above dividend policy


^{※1} Interim dividends 7 yen in FY2021 are derived from other capital surplus, and are excluded from dividend payout ratio

Cross-Shareholdings Reduction

Toward Reducing Cross-Shareholdings

We are currently reviewing the capital efficiency and appropriateness of our cross-shareholdings, and we are in the process of reducing any cross-shareholdings that may not be significant. As of March 31, 2025, the ratio of the Group's cross-shareholdings to consolidated net assets was **16.7%**, owing to sale of **2 securities**. We will **continue to strive for further reductions**.


Cross-Shareholdings Reduction Status



The statistics for FY2020 are for ASKA Pharmaceutical Co., Ltd.
The statistics after FY 2021 are for ASKA Pharmaceutical Holdings Co., Ltd.

Detail of Initiatives 3) Strengthen IR activities

Trend in the number of IR meeting held (including SR meeting)



We will continue to expand opportunities for dialogue and promote improvements in corporate value through dialogue

Key themes of dialogue and areas of interest

Business strategy	Growth in the field of obstetrics and gynecology
	Overseas expansion
	Medium- and long-term growth strategy
Development/ product strategy	Development pipeline
Financial strategy	BS management
	Cost reduction efforts
Business management	Progress on Medium-Term Business Plan

The issues identified during F2Fs are shared with management and reflected in measures as needed

Won the “Best IR Award for Encouragement” of the 2024 IR Award winners for the first time



Overview of FY2024 Initiatives for FY2025



Takashi Yamaguchi,
President, Member of the Board of Directors, Representative Director
ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical Holdings Co., Ltd.

Overview of FY2024

Review of the 4th year of the Medium-Term Management Plan

The Goals of the Medium-Term Management Plan 2025

**"Become a Total Healthcare Company with
a Strong Foundation as a Specialty Pharma Company"**

Targets The Medium-Term Management Plan 2025 Numerical Targets		
Net sales 70.0 billion yen	Operating profit margin 8%	ROE 8%

In response to changes in the external environment, The Medium-Term Management Plan 2025 was designed with four visions and seven strategies.

Specialty Ability to create Social contribution

Medium-Term Management Plan 2025

Summary of the 4th Year and the Target for Last year

The 4th Year of the Medium-Term Management Plan 2025

Net sales	Operating profit	Operating profit margin	Net Profit	ROE8.0%
64.1 billion yen	5.3 billion yen	8.3%	5.1 billion yen	

5th year of the Medium-Term Management Plan

FY2025 Target Net sales: 75.0 billion yen
Operating profit 6.8 billion yen

In addition to steadily building on existing businesses, the consolidation of Hataphar as a subsidiary is expected to enable the achievement of the Medium-Term Management Plan.

7 strategies - Results in the 4th year of the Medium-Term Plan

Strategy

1

Enhance corporate value by strengthening efforts in the specialty area

2

Continuously create new drugs through advanced drug discovery

3

Develop overseas businesses

4

Provide new value to achieve total healthcare

5

Improve operational efficiency, reduce costs, and strengthen financial base

6

Foster an organizational climate that emphasizes thorough compliance and reliability

7

Develop human resources to realize growth strategy

Results in the 4th year of the Medium-Term Plan

- Continued No. 1 ranking in annual sales in the Ob/Gyn field
- Acquired child premium in drug price revision due to addition of pediatric indication of RIFXIMA
- Started specific clinical trial on treatment app AKP-SMD106 under joint research with SUSMED, Inc.
- LF111 application completed, AKP-022 Phase III started, LPRI-CF113 Phase I/II
- Introduction of basic technology for ion channel drug discovery
- Made Hataphar (Vietnam) into a consolidated subsidiary
- Started collaboration with MedChoice (Philippines)
- CVC investments (Dioseve, FamiOne)
- Started PFAS determination service and launched 2 kits for determination of hormone levels in cats
- Continued to take cost reduction measures (FY2020: 54.0%→ FY2024: 51.1%)
- Reexamined portfolio of unprofitable products
- Continued to conduct quality management reviews and compliance training
- Expanded flexible work arrangements and start training program for working internationally
- Certified as a "White 500 enterprise" (4 consecutive years for ASKA Pharmaceutical Holdings, 7 consecutive years for ASKA Pharmaceutical)
- Selected as a "Next Nadeshiko: Companies Supporting Dual-career and Co-parenting"

Mission for the final year of Medium-Term Management Plan 2025

Establish overseas business by maintaining and expanding our business in Japan

Maximize value of existing products

Strive to maintain and strengthen our presence in the OB/GYN field and maximize product value centered on brand-name drugs by continuing to raise disease awareness and provide information

Promote expansion and evolution of pipeline

Expand R&D pipeline and hasten development of drug candidates by utilizing the drug discovery base to leverage in-house drug discovery technologies like ion channel while collaborating with external entities

Achieve total healthcare

Achieve total healthcare, from prevention to treatment and prognosis, by expanding the Femtech business, companion animal products, and noninvasive hormone measurement kits



Establish overseas businesses

Strengthen collaboration with our consolidated subsidiary Hataphar of Vietnam and establish business early

Promote collaboration with MedChoice of the Philippines

ASKA Pharmaceutical Co., Ltd.

■ Main Initiatives


- Specialty Areas
- Development Pipeline
- Overseas Business Development

ASKA Pharmaceutical Co., Ltd.

■ Main Initiatives

- Specialty Areas
- Development Pipeline
- Overseas Business Development


Our Ob/Gyn Pharmaceutical Products by Life Stage

Early childhood	Puberty	Sexual maturity			Menopause	Old age
	Contraception	LF111 (Drospirenone)	ANGE	NORLEVO	Menopause	HOLIN
	Iron deficiency anemia	Riona (Co-Pro*)				
	STD/infection	Rapid SP Chlamydia (Co-pro*)				
	Uterine fibroids Endometriosis Dysmenorrhea Menstrual disorder	RELUMINA Jemina (Co-Pro) PLANOVAR	LEUPRORELIN FREWELL (AG) AKP-SMD106	AKP-022 DroEthi TRM-270	Our Ob/Gyn drugs under development AKP-022 LPRI-CF113 AKP-SMD106	
	Imminent miscarriage/ premature birth, labor induction	Magsent RITODRINE	MAGNESOL ATONIN	Methyl- ergometrine	Expands the lineup and contributes to women's healthcare	
	Infertility	HMG LUTEUM	uFSH GONATROPIN	SEXOVID		
Now on sale	Under development	Trials Completed	Application for approval filed	* Mainly in the field of obstetrics and gynecology		
						 ASKA Pharmaceutical Holdings Co., Ltd.


Growth Driver - RELUMINA (Uterine Fibroids/Endometriosis Agent)

RELUMINA sales trend

*Financial results base (millions of yen)



Endometriosis Market¹



Promote penetration of RELUMINA in the treatment of endometriosis


1. Source: Intage Receipt Data in FY2024 (with duplication due to complications)
April-December 2024: Fixed figures, January-March 2025: Estimated figures

LEP¹ Formulation Market Continues to Expand

In-house count based on Encise data.
All rights reserved.

(Unit: 1000 sheets)

Market trend for LEP formulations



Our LEP formulations³

Jemina[®] tablets

FREWELL[®] COMBINATION TABLETS

DroEthi[®] COMBINATION TABLETS

Increase awareness of diseases through educational activities



Provide treatment options with a lineup of 3 products



Expand share as market for LEP formulations grows

Contribute to improving women's QOL and performance


1. Low-dose Estrogen/Progestin combination 2. Calculated with FY2019 as 100%

3. Co-promotion with Nobelpharma Co., Ltd. for Jemina Tablets

Contribute to Meeting Unmet Medical Needs through RIFXIMA

RIFXIMA sales trend

Based on financial results
(mil yen)



Make steady progress by disseminating Clinical Practice Guidelines for Cirrhosis at points of care and improving awareness of subclinical hepatic encephalopathy

Clinical Practice Guidelines for Cirrhosis 2020

Strength of recommendation: **Strong**

Evidence level: **A**

Issued in November 2020

Enhance recognition of RIFXIMA as a basic therapeutic drug for hepatic encephalopathy


- Strengthen activities in gastroenterological medicine, gastroenterological surgery, and pediatrics
- Promote early diagnosis and treatment by increasing awareness of covert hepatic encephalopathy
- Plan academic conferences and lecture meetings to disseminate evidence

Contribute to improvement of QOL for patients and medical practitioners through total management of complications of cirrhosis

A Leading Company for Thyroid Treatment

Trend in sale of therapeutic agents for thyroid diseases¹

Based on financial results (mil yen)



Share of thyroid products in Japan **95% or more**

Efforts to raise awareness of thyroid diseases through disease education

- ◆ Broadcasting disease awareness videos
- ◆ Publishing disease awareness advertisements
- ◆ Holding public lectures
- ◆ Creating disease awareness materials



Continue disease awareness activities to deliver treatment options to untreated patients

1. THYRADIN, MERCAZOLE, PROPACIL

About Switch to OTC Use of Emergency Contraceptive Pill “NORLEVO”

Press Release



ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch OTC Drug

TOKYO, May 15, 2025 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886), announced that ASKA filed an application with Japanese authorities for manufacturing and marketing approval of the emergency contraceptive pill “NORLEVO” as a switch OTC drug.

Regarding the switch to OTC use of emergency contraceptive pills, the Evaluation and Review Committee began examining the switch to OTC use of emergency-contraceptive pills in 2021. A survey project to prepare an environment for the proper sale of emergency contraceptive pills (test sales of emergency contraceptive pills) is currently being implemented.

Under these circumstances, in order to build a system that can respond to various requests, ASKA filed an application for manufacturing and marketing approval in June 2024. Although the specific timing of approval has not yet been decided, ASKA will keep a close eye on the situation and disclose any information that needs to be announced in a timely and appropriate manner.

Recent trends in the MHLW regarding emergency contraceptive pills

【2021】

The Evaluation and Review Committee began examining the switch to OTC use of emergency-contraceptive pills

【2023-】

A survey project to prepare an environment for the proper sale of emergency contraceptive pills (test sales of emergency contraceptive pills) is currently being implemented

In order to build a system that can respond to various requests, ASKA filed an application for manufacturing and marketing approval in June 2024

ASKA Pharmaceutical Co., Ltd.

■ Main Initiatives

- Specialty Areas
- Development Pipeline
- Overseas Business Development

Pipeline

R&D Status (as of May 16, 2025)

 Changes from the previous financial results meeting

Development code (generic name)/Indication	Research ¹	Non-clinical ¹	Ph I	Ph II	Ph III	Application	Approval
● Ob/Gyn							
LF111 (drospirenone) Contraception							Filed
AKP-022 (relugolix combination tablet) Uterine fibroids					Ph III Ongoing		
AKP-022 (relugolix combination tablet) Endometriosis						Preparing clinical trials	
LPRI-CF113 (drospirenone) Dysmenorrhea				Ph I/II Ongoing			
AKP-SMD106 (digital therapeutics app) PMS/PMDD ²				Specified Clinical Trial Ongoing			
AKP-009 ³ (ludaterone acetate) PCOS ⁴				Preparing clinical trials			
Theme B / Ob/Gyn							
● Internal Medicine							
TRM-270 (adhesion barrier) Gastroenterology and Ob/Gyn						Ph III Completed	
Theme C / Internal Medicine							
● Urology							
AKP-009 (ludaterone acetate) Benign prostatic hyperplasia				Ph II Ongoing			
AKP-021 (mPGES-1 inhibitor agent)			Ph I Ongoing				
AKP-017 (transnasal testosterone)			Preparing clinical trials				

1. Details of research are not disclosed because it is non-clinical 2. Premenstrual syndrome/premenstrual dysphoric disorder

3. AKP009 for PCOS is Theme A 4. Polycystic ovarian syndrome


Overview of Main Ob/Gyn Pipeline (as of May 16, 2025)

	LF111	AKP-022	LPRI-CF113	AKP-009	AKP-SMD106
Generic name	Drospirenone	Relugolix combination tablet (Relugolix Estradiol Norethindrone acetate)	Drospirenone	Ludaterone acetate	-
Indication	Contraception	Uterine fibroids Endometriosis	Dysmenorrhea	Polycystic ovarian syndrome	Premenstrual syndrome/ Premenstrual dysphoric disorder
Development status	Application for approval filed Approval expected in the first half of 2025	Uterine fibroids: Phase III ongoing (Scheduled to be completed on December 31, 2026) Endometriosis: in preparation for development	Ph I/II ongoing (Scheduled to be completed on January 31, 2026)	In preparation for development	Specific clinical trial ongoing (Scheduled to be completed on June 30, 2026)
Market information	Oral contraceptive market Approx. 8.1 billion yen ¹	Uterine fibroids/ endometriosis treatment market Approx. 32.1 billion yen ¹	Menstrual disorder treatment market Approx. 29.4 billion yen ¹	-	-
Expected features	First progestin-only oral contraceptive in Japan and can be used by women who are at risk of thromboembolism, which is a contraindication for estrogen- containing oral contraceptives.	Long-term administration for 6 months or longer will be possible	Progestin agents that can be administered once daily	Next-generation androgen receptor modulator	Non-pharmacological therapy using apps

1. Fuji Keizai Co., Ltd., "Data Book for Prescription Drugs 2024, No. 4." All rights reserved.

Strengthening Drug Discovery Infrastructure

In addition to our conventional drug discovery activities, construct a new drug discovery platform for ion channels and take on the challenge of new modalities



Approach to unmet medical needs in new areas in addition to the 3 core therapeutic areas of Ob/Gyn, internal medicine, and urology

ASKA Pharmaceutical Co., Ltd.

■ Main Initiatives

- Specialty Areas
- Development Pipeline
- Overseas Business Development

Overseas Business Policy

Overseas business policy

- Intensify alliance activities and promote in-licensing and out-licensing on a global basis
- Aim to enter growth markets, establish overseas businesses, and expand collaboration with local companies and distribution channels

Strategies and initiatives in Europe, US, and developed countries

- **In-house drug discovery and alliance activities**
 - Strengthening of drug discovery technology base
 - Introduction of basic technologies for ion channel drug discovery and collaboration with Veneno
 - Global out-licensing/alliance of in-house developed products
- **Global-based in/out-licensing activities**
 - In/out-licensing through partnerships with overseas enterprises
 - Aim to acquire rights in Asia including Japan in the future

Strategies and initiatives in Southeast Asia

- **Establish overseas businesses**
 - Made Hataphar (Vietnam) a consolidated subsidiary
 - Applied for PIC/S-GMP approval for new plant
- **Entry into growth markets**
 - Aiming for synergy with MedChoice (Philippines) in endocrine (thyroid) area
- **Business expansion throughout Southeast Asia**

*Ha Tay Pharmaceutical Joint Stock Company



Aiming for Expansion of overseas operations

ASKA Animal Health Co., Ltd.

ASKA Animal Health - Current Plan and Sales Composition Ratio

Trend in ASKA Animal Health sales

*Based on financial results (million of yen)



Promotes the development of pharmaceuticals for companion animals

ASKA Animal Health

- Priority initiative and field-specific activity status

Priority initiative

Deploy sales activities focused on sale of priority veterinary drugs

Veterinary pharmaceutical

- ✓ **Proposal for improving productivity and reducing costs through a breeding management plan**
Supporting the resolution of practical issues through enhanced sales of reproductive drugs for cattle breeding
- ✓ **Expansion of sales of epidemic prevention products for infectious disease control**
Promote epidemic prevention to expand market penetration by calling attention to the bio-friendly characteristics of our products

Pharmaceuticals for CAs

- ✓ **Strengthen sale of TRILOSTANE TABLETS “ASKA” for hyperadrenocorticism in dogs**

We are striving to expand market share through academic society exhibitions and continuous provision of academic videos

Feed additives

- ✓ **Strengthening responses to the market in line with steady demand for amino acids**

Striving to expand market share by having the product lineup including L-isoleucine

Contributing to the creation of a society where people and animals can coexist in harmony

ASKA Pharma Medical Co., Ltd.

ASKA Pharmaceutical Medical - Priority initiatives

Strengths of ASKA Pharmaceutical Medical - Endogenous hormone microanalysis technologies

Non-invasive testing business

Assay kit for companion animals (cats)
Launched in March 2025



Feline Hyperthyroidism Test Kit
(Hair thyroid hormone measurement)

Feline Stress Test Kit
(Hair cortisol level measurement)



Contributions to animal wellness fairs

Environmental pollutant measurement business

Start of measurement contract

PFAS in blood in Nov. 2024

PFAS in water in Mar. 2025

Measurement of PFAS (per- and polyfluoroalkyl
substances) that exhibit toxicity in vivo

High sensitivity enables measurement with
small sample quantities

Contributing to the creation of a bountifully healthy society
through the latest measurement technology

Overseas Business Development



Sohta Yamaguchi

Senior Managing Member of the Board of Directors, Representative Director

ASKA Pharmaceutical Holdings Co., Ltd.

Overseas Business Policy

Overseas business policy

- Intensify alliance activities and promote in-licensing and out-licensing on a global basis
- Aim to enter growth markets, establish overseas businesses, and expand collaboration with local companies and distribution channels

Strategies and initiatives in Europe, US, and developed countries

- **In-house drug discovery and alliance activities**
 - Strengthening of drug discovery technology base
 - Introduction of basic technologies for ion channel drug discovery and collaboration with Veneno
 - Global out-licensing/alliance of in-house developed products
- **Global-based in/out-licensing activities**
 - In/out-licensing through partnerships with overseas enterprises
 - Aim to acquire rights in Asia including Japan in the future

Strategies and initiatives in Southeast Asia


- **Establish overseas businesses**
 - Made Hataphar (Vietnam) a consolidated subsidiary
 - Applied for PIC/S-GMP approval for new plant
- **Entry into growth markets**
 - Aiming for synergy with MedChoice (Philippines) in endocrine (thyroid) area
- **Business expansion throughout Southeast Asia**

*Ha Tay Pharmaceutical Joint Stock Company

Aiming for Expansion of overseas operations

High-growth Markets - Moving into Vietnam

In-house Analysis of the Southeast Asian market



Socialist Republic of Vietnam

Good security. Stable political situation; friendly toward Japan

Total population:	About 100.31 million ¹ (2023)
GDP growth rate:	Mean of 5-6%/year ¹
Pharmaceutical market:	About 630 billion yen ² (2023)
CAGR:	9.4% ³ (2023)
Generic sales ratio:	About 41% ² (2023)
Foreign company trends:	Local companies account for top 10 in terms of sales History of accepting and collaborating with Japanese and Western companies
Global gender gap index	Ranks 6th out of 18 Eastern Asia and Pacific countries ⁴ (2024)


After considering the high growth markets from various perspectives, we decided to enter Vietnam
Future synergy is expected in ASKA Pharmaceutical's focus areas

1. Asian Development Bank, Dataset 2. Our company's estimation based on IQVIA, Forecast link. All rights reserved.
3. Copyright 2025 IQVIA Incorporated. All rights reserved. CAGR calculated from 2018 to 2023
4. Quoted from the World Economic Forum, Global Gender Gap Report 2024.

Overview of Hataphar

In February 2025, the Company made Hataphar a consolidated subsidiary

Consolidated performance



Description of business

Manufacture and sale of pharmaceuticals

- Generic drugs are its main products, and sales to pharmacies are its strength
- Sells more than 300 of its own products manufactured at La Khe factory in Hanoi

Import and sale

- The distribution network covers all of Vietnam. Handles pharmaceutical products, raw materials, etc.

Other


- Sale and export of raw materials (Cambodia, Myanmar, etc.)

Strengthening entry into the high-end pharmaceutical market with the start of operations at the new factory

Efforts toward a Drug Bidding System and New Factory Operations

Drug bidding system in Vietnam

- ✓ Vietnam has a 3 types of bidding system (national/provincial/medical institutions)
- ✓ Generics are classified into 5 groups based on GMP standards, origin, etc.
WHO-GMP certified products (products manufactured at the existing factory) are classified as G4, and PIC/S GMP certified products (products to be manufactured at the new factory) are classified as G2

Category		Criteria	Price
Brand-Name Drugs		-	High
Generics	G1	EU GMP/Equivalent Origin: Vietnam or developed country Licensed in developed country	
	G2	EU GMP/Equivalent PIC/S GMP Origin: Vietnam or ICH member country	
	G3	WHO-GMP Bio Equivalent study	
	G4	WHO-GMP	
	G5	-	Low



Hataphar's new factory (Hoa Lac High-Tech Park in Hanoi)

Progress of a new factory (in compliance with PIC/S GMP) situation

- ✓ June 2024, Obtained WHO-GMP certification from the Drug Administration of Vietnam
- ✓ August 2024, Obtained approval to manufacture pharmaceuticals from the Drug Administration of Vietnam
- ✓ March 2025, Filed application for PIC/S GMP certification
After obtaining approval, commercial production will commence (scheduled for FY2026).

Aiming for high profits by manufacturing and selling high-quality pharmaceuticals at the new factory

Hataphar - The Next Step

Step1: Made Hataphar a consolidated subsidiary (short-term)

Apply for PIC/S GMP approval for new factory (application filed)
Incorporate ASKA products into Hataphar's portfolio

Step2: Secure a highly profitable structure and prospects for Southeast Asia (mid-term)

Operate new, PIC/S GMP-compliant factory and deploy products
Produce ASKA products and other products for Southeast Asian market

Step3: Expand business in Southeast Asia (mid to long term)


Shift to specialty products with high profitability
Expand business for the Southeast Asian market



Establish a high-profit structure and aim to expand it to the entire Southeast Asian region

High-growth markets - Moving into the Philippines

In-house Analysis of the Southeast Asian market



Republic of the Philippines

Total population:	Approximately 101.19 million ¹ (2023)
GDP growth rate:	Mean of 5-6%/year ¹
Pharmaceutical market:	About 700.0 billion yen ^{*2} (2023)
Foreign company trends:	Foreign-affiliated companies account for a 70% share. Foreign capital restrictions are limited compared to other Southeast Asian countries History of accepting and collaborating with Japanese and Western companies
Global gender gap index:	Ranks 3rd out of 18 Eastern Asia and Pacific countries ³ (2024)

After considering the high growth markets from various perspectives, we decided to collaborate with Philippine corporations. The market growth rate is higher than in other Southeast Asian countries, and a high growth rate is expected in the future as well.

1. Asian Development Bank, Dataset
2. Our company's estimation based on IQVIA, Forecast link. All rights reserved.
3. Quoted from the World Economic Forum, Global Gender Gap Report 2024.

Collaborate with MedChoice of the Philippines

Make FTS Ambrose an equity method affiliated company



March 2025 press release

- MedChoice under FTS has excellent sales and marketing capabilities
- Stands for specialty pharma targeting specific areas and chronic diseases

Pharmaceutical market in the Philippines


- Approx. **700** billion yen¹ pharmaceutical market (as of 2023)
- Annual growth rate of **10.2%**² in pharmaceutical market (2018 to 2023)
The market growth rate is conspicuously higher than in other Southeast Asian countries, and high growth is expected in the future as well.
- Foreign capital restrictions on the pharmaceutical industry are limited (compared to other Southeast Asian countries)
The pharmaceutical import/export business is being liberalized, and there are few restrictions on foreign-affiliated companies.

1. Our company's estimation based on IQVIA, Forecast link. All rights reserved.
2. Copyright 2025 IQVIA Incorporated. All rights reserved.

Overview of MedChoice


Name	MEDCHOICE PHARMA INC. (100% subsidiary of FTS AMBROSE HOLDINGS, INC.)
Location	City of Muntinlupa, Philippines (Manila Metropolitan Area)
Representative	Chairman · Ambrosio V. Padilla III
Number of employees	170
Characteristics	Private maker of branded generics, established in 2005. Has deployed many drugs in the endocrine/CNS areas. 2nd-largest share of Philippine market for thyroid hormone agents

Results for the past 3 years



Aim to create synergies in the specialty area

Vision for overseas business



Expanding overseas operations and aiming for further growth

ASKA Pharmaceutical Holdings - Group Strengths -

Sources of Growth

Specializing in endocrine R&D for a long time

Over **100** years

Developed and launched various products

ASKA Animal Health

Product lineup

Feed additives
Industrial animal/
Companion animal
pharmaceuticals

Launched various products

ASKA Pharmaceutical

A Leading Company
in Ob/Gyn field

Top sales in Ob/Gyn field*

*In-house estimate in FY2024

ASKA Pharma Medical

Measurement technologies

Endogenous hormone
microanalysis technologies

Expansion of non-invasive testing businesses

ASKA Pharmaceutical

A Leading Company
in Thyroid field

Over 95% share of the domestic market for the thyroid treatment


ASKA Pharmaceutical Holdings

Synergy Creation

Intensifying inter-
group cooperation

Cooperation and collaboration in various fields

Become a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company



**ASKA Pharmaceutical Holdings Group
Corporate Message**

For a Healthy Tomorrow and Future.



ASKA Pharmaceutical Holdings Co., Ltd.


Forward-looking Statements

- The forward-looking statements contained in this presentation are based on the Company's assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties.
- Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors.
- This report contains information on Pharmaceutical Products (including those under development), and the content of this report is not intended for medical promotion or medical advice.
- This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.

Appendix

Sales Ratio by Area and Sales Proportion of Brand-name Drugs

Sales Ratio by Area (FY2024)




- Obstetrics and Gynecology
- Internal medicine (Gastroenterology and thyroid)
- Urology
- Others

The total may not add up to 100 because the figures are rounded to the second decimal place.

Sales Proportion of Brand-name Drugs


- Brand-name drugs
- Generic drugs



Aims to increase the ratio of brand-name drugs
(Numerical target in The Medium-Term Management Plan 2025: 70%)

Note: Since 2Q FY2024, we have reviewed the products in the Internal Medicine category and reclassified some products from 'Others' to 'Internal Medicine (Gastrointestinal and Thyroid)'.

ASKA Pharmaceutical: Business Review of the Past 15 Years (Consolidated)



Net Sales/Operating Profit by Quarter (Past Actual)

Performance

Specialty


R&D

Overseas

ESG, etc.


(Millions of yen)

■ Net sales ■ Operating profit



Both sales and profits tend to be low in 4Q due to restrained purchases before periodical NHI drug price revisions and expenses incurred in 4Q.

Sales Trend in ASKA Pharma's Ob/Gyn Products



Number 1 sales* achievement in the field of obstetrics and gynecology has been attained

*In-house estimate

Trends in the Ob/Gyn Market

Performance

Specialty


R&D

Overseas

ESG, etc.

Trends in the obstetrics and gynecology market¹

(billion of yen)



The obstetrics and gynecology market is projected to continue growing

Changes in the environment

- ✓ Promotion of the government's policies on women's empowerment
 - The 2024 Basic Policy on Gender Equality and the 2024 Basic Policy on Gender Equality for Women include information on support for balancing work with health issues, menstruation, pregnancy, childbirth, and menopause, etc.)
 - Establishment of gynecology-specific disease treatment and management fee (2020)
 - Insurance coverage of infertility treatment (2022)
- ✓ Women's advancement in society and changes in lifestyle
 - Increase in the number of female employees and promotion of women to managerial positions
 - Increased awareness of health literacy through increased attention to women's specific health issues and increased exposure in the media and social media, etc.
- ✓ Advances in medical technology and improved access to medical care for women's diseases
 - Development of pharmaceuticals and advances in medical technology related to diseases specific to women, such as treatment of dysmenorrhea and infertility
 - Improved access to health information and expansion of online medical care

1. Fuji Keizai Co., Ltd., "Data Book for Prescription Drugs 2024, No. 4." All rights reserved.

Increase in the Number of Menstrual Cycles due to Changes in Life Events

Many of women today experience their first menstruation earlier, tend to marry later, and experience fewer childbirths than women in past generations.

The increase in the number of menstrual cycles (MCs) experienced in women's lifetime is considered a factor for the increase in dysmenorrhea and other menstrual problems.

Number of MCs experienced by women today

Number of lifetime MCs: **Approx. 450**


Number of lifetime childbirths: **Approx. 2**

Number of MCs experienced by women in past generations

Number of lifetime MCs: **Approx. 50**

Number of lifetime childbirths: **Approx. 5**

Modified from source: Short RV: Rroc. R. Soc. Lond B. Biol. Sci. 1976; 195, 3-24.




Source: National Institute of Population and Social Security Research, Total fertility rate and average age at birth by birth order: 1950-2023

Number of Uterine Fibroids/Endometriosis/ Dysmenorrhea Patients

(Extended estimates from electronic receipt data, 12 months from January of each year to December of the following year)

(Million of patients)




Source: JMDC Claims Database

Estimated Number of Patients in Gynecological Diseases

(in-house estimates from external data)


(Extended estimates from electronic receipt data, 12 months from January of each year to December of the following year)




1 JMDC Corporation survey (expanded estimates from electronic receipt data, period: January 2024 - December 2024)
2 Calculated based on the assumption that the population of women aged 15-49 is 233.9 million and that the incidence rates of endometriosis, dysmenorrhea, and uterine fibroids are 10%, 30%, and 25%, respectively, based on various reports.

Uterine Fibroids/Endometriosis Market

Uterine Fibroid Market



Endometriosis Market



Source: Intage Receipt Data in FY2024 (with duplication due to complications)
April-December 2024: Fixed figures, January-March 2025: Estimated figures

TechDoctor and ASKA Pharmaceutical Launch Joint Research on Dysmenorrhea in Cooperation with Healthcare App "4MOON"



TechDoctor and ASKA Pharmaceutical Launch Joint Research on Dysmenorrhea in Cooperation with Healthcare App "4MOON"

Leveraging data from wearable devices to grasp the actual status of menstrual symptoms and to evaluate the severity of dysmenorrhea and other symptoms in the future

TOKYO, September 24, 2024 – TechDoctor, Inc. (Head Office: Chuo-ku, Tokyo/ President: Kazumichi Minato, hereinafter "TechDoctor") and ASKA Pharmaceutical Co. Ltd., (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter "ASKA") announced that the companies launched the joint research on dysmenorrhea in cooperation with the healthcare app: 4MOON.

This research will be conducted with the cooperation of users of 4MOON, a health care application provided by 4MEEE INC. (Head Office: Shinjuku-ku, Tokyo/ President: Kazuya Oku, hereinafter "4MEEE"). By utilizing data collected from wearable devices to accurately grasp the actual physical and psychological symptoms associated with menstruation, the research aims to develop a digital biomarker[1] that quantitatively indicates the severity of dysmenorrhea and other symptoms in the future.

By utilizing data, the research aims to develop a digital biomarker

ASKA and SUSMED Start Specified Clinical Trial Using Digital Therapeutics App Designed for Patients with PMS/PMDD



ASKA and SUSMED Start Specified Clinical Trial Using Digital Therapeutics App Designed for Patients with PMS/PMDD

ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/Representative Director: Sohta Yamaguchi, hereinafter "ASKA") and SUSMED, Inc. (Head Office: Chuo-ku, Tokyo/Representative Director: Taro Ueno, hereinafter "SUSMED") announced that two companies started a specified clinical trial (hereinafter referred to as the "Trial") using a digital therapeutics app (hereinafter the "App") designed for patients with Premenstrual Syndrome (hereinafter "PMS") or Premenstrual Dysphoric Disorder (hereinafter "PMDD"), in collaboration with Mariko Ogawa, Ph.D., a specially-appointed professor at Fukushima Medical Center for Children and Woman of Fukushima Medical University. The Trial will also utilize SUSMED's clinical trial system (SUSMED Source Data Sync®, hereinafter "SUSMED SDS"), which implements SUSMED's blockchain technology with the aim of improving the efficiency and quality of acquired data.

Through research and development of digital therapeutics app, ASKA and SUSMED aim to provide new treatment options for PMS and PMDD

Tackling women's health issues with new approaches in addition to conventional ones

RIFXIMA Related Topic: Activities to Propose Early Diagnosis/ Treatment of Complications of Cirrhosis

Performance

Specialty


R&D

Overseas

ESG, etc.

● Prevalence of covert hepatic encephalopathy*1

In liver cirrhosis patients, the prevalence of covert hepatic encephalopathy increases with higher Child-Pugh score.*2



Hanai T, et al. J Gastroenterol Hepatol. 2019; 34(10): Reproduced from 1809-1816.

Description of covert hepatic encephalopathy in the Clinical Practice Guidelines for Cirrhosis

CQ 4-12

(4) 肝性脳症

不顕性肝性脳症に対して治療は必要か？

推奨

- 背景肝の状況が悪化しているなどの高リスクを有する不顕性肝性脳症の症例には治療を提案する。

【推奨の強さ：弱（合意率 100%），エビデンスレベル：B】

[Strength of recommendation]

Strong (strong recommendation): Recommend to “implement” / Recommend not to “implement”

Weak (weak recommendation): Recommend to “implement” / Recommend not to “implement”

[Quality of evidence]

A: High-quality evidence (High) - We can be confident that the true effect is close to the estimated effect.

B: Moderate-quality evidence (Moderate) - The estimated effect is moderately reliable.

The true effect is probably close to the estimated effect, but it may differ substantially.

C: Low-quality evidence (Low) ... Confidence in the effect estimate is limited.

The true effect may differ substantially from the effect estimate.

D: Very low-quality evidence (Very Low) ... The effect estimate is almost certainly unreliable.

The true effect is likely to be substantially different from the effect estimate.

From the Japanese Society of Gastroenterology and the Japan Society of Hepatology,
Clinical Practice Guidelines for Liver Cirrhosis 2020 (3rd edition)


**Contributes to patient QOL by expanding early diagnosis and
treatment for complications of cirrhosis in clinical practice**

*1 Hepatic encephalopathy with few clinical symptoms. It has been reported to worsen life prognosis in Japan as well.

*2 Used to classify the severity of cirrhosis. Three levels of severity (grades) based on total score for 5 clinical parameters.




Outcomes of Thyroid Awareness Activities



TSH testing increased 1.35 times in FY2022 compared to FY2015

◆ What are ion channels?

- membrane proteins passing ions across cell membranes
- involving the release of chemical transmitters, control of hormone secretion, etc.
- attractive target molecules for a variety of disease conditions



Type	Condition
Ca²⁺ channel	Arrhythmia, diabetes, muscular dystrophy, epilepsy, hypertension, migraine, muscular dysgenesis, cerebral infarction, pain
Cl⁻ channel	Cystic fibrosis, nephrolithiasis, myotonia
K⁺ channel	Arrhythmia, bronchial asthma, ataxia, hypertension, myocardial infarction, deafness, diabetes, epilepsy, cancer, glaucoma, immunosuppression
Na⁺ channel	Arrhythmia, epilepsy, migraine, myotonia, sharp pain, paralysis, cerebral infarction
Ligand-gated ion channel	Allergic diseases, bronchial asthma, epilepsy, reflux esophagitis, migraine, Parkinson's disease, Huntington's disease, pain, cerebral infarction, gastric ulcer, constipation

Modified from: Ion Channels as Therapeutic Targets for Multiple Diseases (2002)

About Polycystic Ovary Syndrome (PCOS)

Performance

Specialty

R&D

Overseas

ESG, etc.

What is Polycystic Ovary Syndrome?

Polycystic ovary syndrome is a disease in which the follicles stop growing and many small follicles (cysts) remain in the ovaries. Abnormal gonadotropin secretion and excess male hormones are thought to be the reasons for the failure of follicle growth. Although it may be unfamiliar to many, it is said to occur in 5-8% of women in their sexual maturity (20s-45 years old).

Main Symptoms

Since follicles do not grow and ovulation does not occur regularly, abnormalities in the menstrual cycle (amenorrhea, oligomenorrhea) appear, which can cause infertility. Other symptoms that may occur due to male hormones include hairiness, acne, obesity, and elevated blood sugar levels. If left untreated for a long period of time, it is said to increase the risk of uterine cancer and metabolic syndrome.

Diagnostic Methods

Polycystic ovary syndrome is diagnosed when the following three characteristics are met

Abnormal menstrual cycle
Ultrasonography shows many undeveloped follicles in the ovaries.

(3) Blood tests show high levels of male hormones and luteinizing hormone (a hormone that promotes ovulation).

(hormones that stimulate ovulation) are high in blood tests.

Treatment Methods

At that point, treatment will proceed based on whether or not a pregnancy is desired.

- If you wish to conceive
Hormone therapy is used to stimulate ovulation and achieve pregnancy.
Surgery may be performed to facilitate ovulation.
- If you do not wish to become pregnant
In order to ensure proper menstruation, progestin or E/P (estrogen/progesterone) or E/P (estrogen and progesterone) combination drugs are prescribed to ensure proper menstruation.
In addition, if the patient is obese, the symptoms tend to be more severe, and lifestyle modification, including weight loss, may be necessary.
Lifestyle modifications, including weight loss, may be necessary.

Vietnamese and Philippine Pharmaceutical Markets

Performance


Specialty

R&D


Overseas

ESG, etc.

Vietnamese pharmaceutical market



Philippine pharmaceutical market



Both original and generic drugs are expanding

Social Contribution Activities: Health Lab Mint⁺ for Women's Health

Performance

Specialty

R&D

Overseas

ESG, etc.



Established in 2020 on the occasion of 100th anniversary of the Company



Health Lab Mint⁺ for Women's health

Key message

Knowing yourself, is protecting yourself



Disseminating accurate information under physician supervision improves women's health literacy

Mint⁺Hug Website for those who are raising children



Focus on pregnancy, childbirth, and the health of infants

- Columns for Moms
- Column on newborns/infants
- Helpful information on raising children

*Update as needed

Mint⁺teens

Website for teens



Femknowledge

Video training service for companies



Contribution to ESG 11 Material Issues and Women's Health

Performance

Specialty

R&D

Overseas

ESG, etc.

Environmental

- Environmental protection and continuous reduction of environmental impact

Social

- **Contribution to women's health**
- Contribution to animal health
- Human resource development
- Employee engagement
- Creation of innovative products
- Expanding access to healthcare
- Stable supply of high-quality products
- Promotion of proper use of products

Governance

- Corporate governance
- Secure compliance with laws and regulations, enforcement of compliance

Issues we are addressing to help women live fulfilling lives

Economic loss related to menstrual symptoms
as estimated by the Company*

Contributed to **42.8 billion yen reduction** in economic loss through the provision of ASKA Pharmaceutical products



**Solving social issues related to women's health as a
“leading company in the field of obstetrics and gynecology”**

1. Calculated based on the Ministry of Economy, Trade and Industry's "Estimation of economic loss due to female-specific health issues and necessity of health management"

2. The Company's estimate Reduction in annual economic loss due to ASKA's pharmaceuticals = Reduction in annual economic loss due to medical care for women's menstrual symptoms x Percentage of annual economic loss avoided through ASKA's pharmaceuticals,
Percentage of annual economic loss avoided through ASKA's pharmaceuticals = Number of people taking ASKA's pharmaceuticals ÷ Number of female workers who have symptoms associated with menstruation and take actions

Human Capital Initiatives

Performance

Specialty


R&D

Overseas

ESG, etc.

Female advancement

Percentage of female managers among regular employees



received an award in “Tokyo Women's Empowerment Awards” in the first time



Health management

Internal systems


- ✓ **Work Support Bonus**
Work support bonus paid every 6 months to employees who support co-workers who must temporarily leave the workplace owing to life events



Achieved for 7 consecutive years

Development of next generation

The male childcare leave utilization rate has achieved 100%



Selected under the “Next Nadeshiko: Companies Supporting Dual-career and Co-parenting” in the first time




Opportunity for dialogue with management

Number of opportunities: 62
Time: 113 hours

(Results for FY2024)

Employee engagement



Dialogue with the management team leads to improved work engagement

Initiatives/External Evaluation

Performance

Specialty

R&D

Overseas

ESG, etc.

Initiatives



ESG External Evaluation



External Evaluation



Inquiries

Corporate Planning Department

Tel : +81-3-5484-8366

e-mail: kouhou@aska-pharma.co.jp